These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

343 related articles for article (PubMed ID: 33339633)

  • 1. A clinical protocol of a comparative effectiveness trial of extended-release naltrexone versus extended-release buprenorphine with individuals leaving jail.
    Gordon MS; Mitchell SG; Blue TR; Vocci FJ; Fishman MJ; Murphy SM; Couvillion K; Maher K; Ryan D; Wenzel K; Danner ML; Jarvis DK
    J Subst Abuse Treat; 2021 Sep; 128():108241. PubMed ID: 33339633
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized comparison of extended-release naltrexone with or without patient navigation vs enhanced treatment-as-usual for incarcerated adults with opioid use disorder.
    Farabee D; Condon T; Hallgren KA; McCrady B
    J Subst Abuse Treat; 2020 Oct; 117():108076. PubMed ID: 32811623
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Perceptions of extended-release naltrexone, methadone, and buprenorphine treatments following release from jail.
    Velasquez M; Flannery M; Badolato R; Vittitow A; McDonald RD; Tofighi B; Garment AR; Giftos J; Lee JD
    Addict Sci Clin Pract; 2019 Oct; 14(1):37. PubMed ID: 31570100
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Health and economic outcomes of treatment with extended-release naltrexone among pre-release prisoners with opioid use disorder (HOPPER): protocol for an evaluation of two randomized effectiveness trials.
    Murphy SM; Jeng PJ; Poole SA; Jalali A; Vocci FJ; Gordon MS; Woody GE; Polsky D
    Addict Sci Clin Pract; 2020 Apr; 15(1):15. PubMed ID: 32321570
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Extended-release naltrexone opioid treatment at jail reentry (XOR).
    McDonald RD; Tofighi B; Laska E; Goldfeld K; Bonilla W; Flannery M; Santana-Correa N; Johnson CW; Leibowitz N; Rotrosen J; Gourevitch MN; Lee JD
    Contemp Clin Trials; 2016 Jul; 49():57-64. PubMed ID: 27178765
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Opioid treatment at release from jail using extended-release naltrexone: a pilot proof-of-concept randomized effectiveness trial.
    Lee JD; McDonald R; Grossman E; McNeely J; Laska E; Rotrosen J; Gourevitch MN
    Addiction; 2015 Jun; 110(6):1008-14. PubMed ID: 25703440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Extended-release naltrexone for youth with opioid use disorder.
    Mitchell SG; Monico LB; Gryczynski J; Fishman MJ; O'Grady KE; Schwartz RP
    J Subst Abuse Treat; 2021 Nov; 130():108407. PubMed ID: 34118699
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.
    Lee JD; Nunes EV; Novo P; Bachrach K; Bailey GL; Bhatt S; Farkas S; Fishman M; Gauthier P; Hodgkins CC; King J; Lindblad R; Liu D; Matthews AG; May J; Peavy KM; Ross S; Salazar D; Schkolnik P; Shmueli-Blumberg D; Stablein D; Subramaniam G; Rotrosen J
    Lancet; 2018 Jan; 391(10118):309-318. PubMed ID: 29150198
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cost-effectiveness of extended-release injectable naltrexone among incarcerated persons with opioid use disorder before release from prison versus after release.
    Jalali A; Jeng PJ; Polsky D; Poole S; Ku YC; Woody GE; Murphy SM
    J Subst Abuse Treat; 2022 Oct; 141():108835. PubMed ID: 35933942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expanding access to Medication for Opioid Use Disorder (MOUD) in jails: A comprehensive program evaluation.
    Pourtaher E; Gelberg KH; Fallico M; Ellendon N; Li S
    J Subst Use Addict Treat; 2024 Jun; 161():209248. PubMed ID: 38081540
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Maintenance on extended-release naltrexone is associated with reduced injection opioid use among justice-involved persons with opioid use disorder.
    Lier AJ; Seval N; Vander Wyk B; Di Paola A; Springer SA
    J Subst Abuse Treat; 2022 Nov; 142():108852. PubMed ID: 35988513
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Extended release naltrexone injection is performed in the majority of opioid dependent patients receiving outpatient induction: a very low dose naltrexone and buprenorphine open label trial.
    Mannelli P; Wu LT; Peindl KS; Swartz MS; Woody GE
    Drug Alcohol Depend; 2014 May; 138():83-8. PubMed ID: 24602363
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The SOMATICS collaborative: Introduction to a National Institute on Drug Abuse cooperative study of pharmacotherapy for opioid treatment in criminal justice settings.
    Chandler RK; Finger MS; Farabee D; Schwartz RP; Condon T; Dunlap LJ; Zarkin GA; McCollister K; McDonald RD; Laska E; Bennett D; Kelly SM; Hillhouse M; Mitchell SG; O'Grady KE; Lee JD
    Contemp Clin Trials; 2016 May; 48():166-72. PubMed ID: 27180088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Extended-release naltrexone for opioid use disorder started during or following incarceration.
    Lincoln T; Johnson BD; McCarthy P; Alexander E
    J Subst Abuse Treat; 2018 Feb; 85():97-100. PubMed ID: 28479011
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between methadone or buprenorphine use during medically supervised opioid withdrawal and extended-release injectable naltrexone induction failure.
    Shulman M; Choo TH; Scodes J; Pavlicova M; Wai J; Haenlein P; Tofighi B; Campbell ANC; Lee JD; Rotrosen J; Nunes EV
    J Subst Abuse Treat; 2021 May; 124():108292. PubMed ID: 33771287
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Buprenorphine-naloxone vs. extended-release naltrexone for opioid use disorder in individuals with and without criminal legal involvement: A secondary analysis of the X:BOT randomized controlled trial.
    Balter DR; Puglisi LB; Dziura J; Fiellin DA; Howell BA
    J Subst Use Addict Treat; 2024 Sep; 164():209438. PubMed ID: 38857827
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-acting buprenorphine vs. naltrexone opioid treatments in CJS-involved adults (EXIT-CJS).
    Waddell EN; Springer SA; Marsch LA; Farabee D; Schwartz RP; Nyaku A; Reeves R; Goldfeld K; McDonald RD; Malone M; Cheng A; Saunders EC; Monico L; Gryczynski J; Bell K; Harding K; Violette S; Groblewski T; Martin W; Talon K; Beckwith N; Suchocki A; Torralva R; Wisdom JP; Lee JD
    J Subst Abuse Treat; 2021 Sep; 128():108389. PubMed ID: 33865691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lorcaserin treatment for extended-release naltrexone induction and retention for opioid use disorder individuals: A pilot, placebo-controlled randomized trial.
    Levin FR; Mariani JJ; Pavlicova M; Choi CJ; Basaraba C; Mahony AL; Brooks DJ; Naqvi N; Bisaga A
    Drug Alcohol Depend; 2021 Feb; 219():108482. PubMed ID: 33418204
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Injectable pharmacotherapy for opioid use disorders (IPOD).
    Farabee D; Hillhouse M; Condon T; McCrady B; McCollister K; Ling W
    Contemp Clin Trials; 2016 Jul; 49():70-7. PubMed ID: 27282118
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reductions in tobacco use in naltrexone, relative to buprenorphine-maintained individuals with opioid use disorder: Secondary analysis from the National Drug Abuse Treatment Clinical Trials Network.
    Montgomery L; Winhusen T; Scodes J; Pavlicova M; Twitty D; Campbell ANC; Wang AL; Nunes EV; Rotrosen J
    J Subst Abuse Treat; 2021 Nov; 130():108489. PubMed ID: 34118716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.